Parallax Volatility Advisers
ACAD icon

Parallax Volatility Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Parallax Volatility Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-856
Closed -$26.8K – 1766
2023
Q4 		$26.8K Buy
+856
New +$20.4K ﹤0.01% 1971
2023
Q2 		– Sell
-2,555
Closed -$56.8K – 2324
2023
Q1 		$48.1K Buy
+2,555
New +$48.7K ﹤0.01% 2221
2020
Q4 		– Sell
-51,217
Closed -$2.11M – 3256
2020
Q3 		$2.11M Buy
+51,217
New +$2.21M ﹤0.01% 1685
2019
Q1 		– Sell
-16
Closed – – 2690
2018
Q4 		$0 Sell
16
-777
-98% -$15.1K ﹤0.01% 2842
2018
Q3 		$16K Sell
793
-49
-6% -$771 ﹤0.01% 2176
2018
Q2 		$13K Buy
+842
New +$15K ﹤0.01% 1718
2018
Q1 		– Sell
-607
Closed -$16.8K – 2137
2017
Q4 		$18K Sell
607
-10,875
-95% -$348K ﹤0.01% 3693
2017
Q3 		$433K Sell
11,482
-15,214
-57% -$495K ﹤0.01% 1288
2017
Q2 		$745K Buy
+26,696
New +$796K ﹤0.01% 1118

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Parallax Volatility Advisers's ACAD Position: Q1 2024 in Review

Parallax Volatility Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 856 shares — an estimated $26.8K sold.

Parallax Volatility Advisers first reported a position in ACAD in Q2 2017 and held it in 9 quarters. The position peaked at $2.11M in Q3 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Parallax Volatility Advisers reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Parallax Volatility Advisers sold 856 Acadia Pharmaceuticals shares in Q1 2024, an estimated $26.8K.
  • Parallax Volatility Advisers first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 9 quarters.
  • Parallax Volatility Advisers's Acadia Pharmaceuticals position peaked at $2.11M in Q3 2020.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Parallax Volatility Advisers's 13F filing for Q1 2024, filed 15 May 2024.